Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis

The polyene antibiotic amphotericin B is currently a second-line treatment for visceral leishmaniasis (VL) and mucocutaneous leishmaniasis. Lipid-amphotericin B formulations with lower toxicity than the parent drug that were developed for the treatment of systemic mycoses have proved to be an effective treatment for VL, especially AmBisome, a small unilamellar negatively charged liposome. In vitro, free amphotericin B was three to six times more active than the liposomal formulation AmBisome against both Leishmania major promastigotes in culture and amastigotes in murine macrophages. In a BALB/c L. major model of cutaneous infection, liposomal amphotericin B administered once a day on six alternate days by the intravenous route produced a dose-response effect between 6.25 and 50 mg/kg. Liposomal amphotericin B administered subcutaneously close to a lesion had no significant activity. Free drug was ineffective at nontoxic doses. The results suggest that liposomal amphotericin B may be useful in the treatment of cutaneous leishmaniasis.

[1]  D. Heyneman.  Immunology of leishmaniasis. , 1971, Bulletin of the World Health Organization.

[2]  C J Marinkelle,et al.  The control of leishmaniases. , 1980, Bulletin of the World Health Organization.

[3]  R. New,et al.  The treatment of experimental cutaneous leishmaniasis with liposome-entrapped Pentostam , 1980, Parasitology.

[4]  R. New,et al.  Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes. , 1981, The Journal of antimicrobial chemotherapy.

[5]  F. Szoka,et al.  Treatment of experimental cutaneous leishmaniasis with liposome-intercalated amphotericin B , 1984, Antimicrobial Agents and Chemotherapy.

[6]  F. Modabber,et al.  Increased myelopoiesis during Leishmania major infection in mice: generation of 'safe targets', a possible way to evade the effector immune mechanism. , 1986, Clinical and experimental immunology.

[7]  J. Berman,et al.  Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys , 1986, Antimicrobial Agents and Chemotherapy.

[8]  A. Bhaduri,et al.  Mechanism of action of amphotericin B on Leishmania donovani promastigotes. , 1986, Molecular and biochemical parasitology.

[9]  S. Allen,et al.  The in vitro Susceptibility of Macrophages Infected with Amastigotes of Leishmania spp. to Pentavalent Antimonial Drugs and Other Compounds with Special Relevance to Cutaneous Isolates , 1989 .

[10]  L. Schnur.  Control of the leishmaniases. Report of a WHO Expert Committee. , 1992, World Health Organization technical report series.

[11]  G. Gregoriadis.  Overview of liposomes. , 1991, The Journal of antimicrobial chemotherapy.

[12]  J. Adler-Moore,et al.  Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. , 1991, The Journal of antimicrobial chemotherapy.

[13]  J. Bertino,et al.  Effect of variation in infusion time and macrophage blockade on organ uptake of amphotericin B-deoxycholate. , 1991, The Journal of antimicrobial chemotherapy.

[14]  D. Crommelin,et al.  Liposomal and Lipid Formulations of Amphotericin B , 1992, Clinical pharmacokinetics.

[15]  P. Stahl,et al.  Transport of phagosomal components to an endosomal compartment. , 1992, The Journal of biological chemistry.

[16]  E. Handman,et al.  Persistence of virulent Leishmania major in murine cutaneous leishmaniasis: a possible hazard for the host , 1993, Infection and immunity.

[17]  T. Allen,et al.  Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection. , 1993, Biochimica et biophysica acta.

[18]  J. Berman,et al.  Treatment of Brazilian kala-azar with a short course of amphocil (amphotericin B cholesterol dispersion). , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  D Needham,et al.  Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. , 1993, Cancer research.

[20]  L. Gradoni,et al.  Activity of liposomal amphotericin B (AmBisome) against Leishmania infantum and tissue distribution in mice. , 1993, Journal of drug targeting.

[21]  H. Murray.  Blood monocytes: differing effector role in experimental visceral versus cutaneous leishmaniasis. , 1994, Parasitology today.

[22]  Relapse of visceral leishmaniasis in patients who were coinfected with human immunodeficiency virus and who received treatment with liposomal amphotericin B. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  R. Janknegt,et al.  Clinical use of liposomal and lipid-complexed amphotericin B. , 1994, The Journal of antimicrobial chemotherapy.

[24]  J. Bolard,et al.  The endocytic process in CHO cells, a toxic pathway of the polyene antibiotic amphotericin B , 1994, Antimicrobial Agents and Chemotherapy.

[25]  S. Khoo,et al.  Administering amphotericin B--a practical approach. , 1994, The Journal of antimicrobial chemotherapy.

[26]  G. Lopez-Berestein,et al.  Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: role of lipid transfer protein. , 1994, Journal of pharmaceutical sciences.

[27]  L. Gradoni,et al.  Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. , 1994, The Quarterly journal of medicine.

[28]  J. Prada,et al.  Successful treatment of antimony-resistant cutaneous leishmaniasis with liposomal amphotericin B. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  Successful treatment of resistant visceral leishmaniasis with liposomal amphotericin B. , 1994, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[30]  G. Lopez-Berestein,et al.  The interaction of liposomal amphotericin B and serum lipoproteins within the biological milieu. , 1994, Journal of drug targeting.

[31]  T. Theander,et al.  Antigen‐presenting cells in human cutaneous leishmaniasis due to Leishmania major , 1995, Clinical and experimental immunology.

[32]  T. Singh,et al.  Use of amphotericin B in drug-resistant cases of visceral leishmaniasis in north Bihar, India. , 1995, The American journal of tropical medicine and hygiene.

[33]  Y. Belkaid,et al.  Parasite-host relationships: in-situ study of Leishmania spp. in resistant and susceptible mice. , 1995, Annals of tropical medicine and parasitology.

[34]  A. Bryceson,et al.  Treatment of Mediterranean visceral leishmaniasis. , 1995, Bulletin of the World Health Organization.

[35]  D. Papahadjopoulos,et al.  Liposomes revisited , 1995, Science.

[36]  R. Dietze,et al.  Treatment of kala-azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days. , 1995, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[37]  Internalization of amphotericin B and other polyene antifungals in mammalian cells: a possible origin of their toxicity. , 1995 .

[38]  M. T. ten Kate,et al.  Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans. , 1995, The Journal of antimicrobial chemotherapy.

[39]  R. Wilkinson,et al.  Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  G. De Nucci,et al.  Ex vivo evidence for PGE2 and LTB4 involvement in cutaneous leishmaniasis: relation with infection status and cytokine production , 1996, Parasitology.

[41]  P. Legrand,et al.  Comparative internalization and recycling of different amphotericin B formulations by a macrophage-like cell line. , 1996, The Journal of antimicrobial chemotherapy.